secwatch.observer — SEC 8-K summary
======================================

Issuer:     Molecular Templates, Inc. (—)
CIK:        0001183765
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001171843-24-002920
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Molecular Templates Q1 net income $0.6M on revenue $11.1M; MT-6402 shows 2 PRs in HNSCC
--------------------------------------------------------------------------------

- Net income $0.6M ($0.11 basic EPS) vs $10.8M ($2.89) in Q1 2023; revenue $11.1M vs $36.6M.
- Cash and equivalents $6.8M; subsequent $9.5M financing closing supports ops into Q4 2024.
- MT-6402 monotherapy in HNSCC: 2 confirmed PRs (ongoing 10 & 20 months), 4 SDs in 7 evaluable.
- MT-8421 Phase 1 dose escalation ongoing; unique Treg depletion pharmacodynamics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1183765/000117184324002920/0001171843-24-002920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1183765/000117184324002920/f8k_051524.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-002920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer